PowerUp Acquisition (PWUP) Competitors

Kiora Pharmaceuticals (NASDAQ:KPRX) and PowerUp Acquisition (NASDAQ:PWUP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.

Which has more volatility and risk, KPRX or PWUP?

Kiora Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, PowerUp Acquisition has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.

Does the MarketBeat Community believe in KPRX or PWUP?

Kiora Pharmaceuticals received 18 more outperform votes than PowerUp Acquisition when rated by MarketBeat users.

Company	Underperform	Outperform
Kiora Pharmaceuticals	Outperform Votes 18 75.00%	Underperform Votes 6 25.00%
PowerUp Acquisition	N/A	N/A

Which has stronger earnings and valuation, KPRX or PWUP?

PowerUp Acquisition has lower revenue, but higher earnings than Kiora Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16M	0.57	-$12.51M	-$2.90	-1.04
PowerUp Acquisition	N/A	N/A	N/A	N/A	N/A

Do institutionals and insiders believe in KPRX or PWUP?

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of PowerUp Acquisition shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 48.0% of PowerUp Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is KPRX or PWUP more profitable?

Kiora Pharmaceuticals' return on equity of 21.32% beat PowerUp Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	21.32%	16.39%
PowerUp Acquisition	N/A	N/A	N/A

Do analysts prefer KPRX or PWUP?

Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 231.13%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kiora Pharmaceuticals is more favorable than PowerUp Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PowerUp Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor KPRX or PWUP?

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than PowerUp Acquisition. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for PowerUp Acquisition. Kiora Pharmaceuticals' average media sentiment score of 1.44 beat PowerUp Acquisition's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Positive
PowerUp Acquisition	Neutral

Summary

Kiora Pharmaceuticals beats PowerUp Acquisition on 10 of the 12 factors compared between the two stocks.